The pharmaceutical industry is on the cusp of a revolution, thanks to the advent of generative artificial intelligence (AI) technology. This innovative approach is transforming the traditional drug development process, which has long been plagued by high costs, lengthy timelines, and low success rates. With AI, scientists can digitally design drug molecules, which are then physically created and tested for their interaction with target proteins. The results are fed back into the AI software, accelerating the development process. While AI-developed drugs are already in clinical trials, experts acknowledge that there is still much to be learned. The technology holds great promise, however, with the potential to significantly reduce the time and cost associated with traditional drug development, which can take up to 15 years and cost an average of $1 billion.
AI Revolutionizes Drug Development
Generative A.I. is transforming the field, but the drug-development process is messy and very human.
1–2 minutes
TOP STORIES
Nvidia’s Vera Rubin platform is set to revolutionize AI inference with unmatched performance …
Apple’s leadership transition highlights a strategic focus on silicon for AI innovation …
Tennessee’s new law restricts AI claims in mental health but may create loopholes …
Experts warn that as AI evolves, the risks it poses are becoming more serious and complex …
China sets new regulations for AI companions, impacting a booming market …
Anthropic continues to engage with the Trump administration despite Pentagon tensions …
